Q5165 Denosumab-mobz - CanMED: HCPCS

Return Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Denosumab-mobz

Brand Name:

Oziltus

Strength:

1mg

HCPCS:

Q5165

SEER*Rx Category:

Ancillary Therapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

RANKL

Oral (Y/N):

No

FDA Approval Year:

2025

FDA Discontinuation Year:

CMS Effective Date:

June 17, 2026

CMS Discontinuation Date:

Status:

In Use